Are all high-grade breast cancers with no steroid receptor hormone expression alike? The special case of the medullary phenotype

Annals of Oncology

Volumn 16, Issue 7, 2005, Pages 1094-1099

  Orlando, Laura ^a   Renne, G ^a   Rocca, A ^a   Curigliano, G ^a   Colleoni, M ^a   Severi, G ^a   Peruzzotti, G ^a   Cinieri, S ^b   Viale, G ^a   Sanna, G ^a   Goldhirsch, A ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b NONE

Author keywords

Breast cancer; Medullary Phenotype; Pathological features

Indexed keywords

ANTINEOPLASTIC AGENT; CD3 ANTIGEN; CD68 ANTIGEN; CYCLIN E; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE RECEPTOR; KI 67 ANTIGEN; PROTEIN P21; PROTEIN P27; PROTEIN P53; STEROID RECEPTOR; TENASCIN; UVOMORULIN; TUMOR MARKER;

ADULT; AGED; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER GRADING; CANCER INVASION; CANCER PATIENT; CANCER RELAPSE; CELL COUNT; CELL INFILTRATION; CELL INTERACTION; CELL PROLIFERATION; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEALTH CARE FACILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; MASTECTOMY; MEDULLARY CARCINOMA; MICROENVIRONMENT; PATIENT SELECTION; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE; TUMOR GROWTH; BREAST TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, MEDULLARY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PHENOTYPE; RECEPTORS, STEROID; TUMOR MARKERS, BIOLOGICAL;

EID: 25444501219     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdi213     Document Type: Article

References (30)

1. Moore OS Jr, Foote FW Jr. The relatively favorable prognosis of medullary breast carcinoma of the breast. Cancer 1949; 2: 635-642.
2. Richardson WW. Medullary carcinoma of the breast. A distinctive tumor type with a relatively good prognosis following radical mastectomy. Br J Cancer 1956; 10: 415-423.
3. Jensen ML, Kiaer H, Andersen J et al. Prognostic comparison of three classifications for medullary carcinoma of the breast. Histopathology 1997; 30: 523-532.
4. Ridolfi R, Rosen P, Port A et al. Medullary carcinoma of the breast. A clinicopathologic study with 10 year follow-up. Cancer 1977; 40: 1365-1385.
5. Reiner A, Reiner G, Spona J et al. Histopathologic characterization of human breast cancer in correlation with estrogen receptor status. A comparison of immunocytochemical and biochemical analysis. Cancer 1988; 61: 1149-1154.
6. de Cremoux P, Salomon AV, Liva S et al. p53 mutation as a genetic trait of typical medullary breast carcinoma. J Natl Cancer Inst 1999; 91: 641-643.
7. Dendale R, Vincent-Salomon A, Mouret-Fourme E et al. Medullary breast carcinoma: Prognostic implications of p53 expression. Int J Biol Markers 2003; 18: 99-105.
8. Piccart MJ, Di Leo A, Hamilton A. HER2. A 'predictive factor' ready to use in the daily management of breast cancer patients? Eur J Cancer 2000; 36: 1755-1761.
9. Hansen MH, Nielsen H, Ditzel HJ. The tumor-infiltrating B cell response in medullary breast cancer is oligoclonal and directed against the autoantigen actin exposed on the surface of apoptotic cancer cells. Proc Natl Acad Sci USA 2001; 98: 12659-12664.
10. Coronella JA, Telleman P, Kingsbury GA et al. Evidence for an antigen-driven Immoral immune response in medullary ductal breast cancer. Cancer Res 2001; 61: 7899-7899.
11. Yakirevic E, Maroun L, Cohen O et al. Apoptosis, proliferation, and Fas (APO-1, CD95)/Fas ligand expression in medullary carcinoma of the breast. J Pathol 2000; 192: 166-173.
12. Elledge RM, Allred DC. Prognostic and predictive value of p53 and p21 in breast cancer. Breast Cancer Res Treat 1998; 52: 79-98.
13. kipl expression and interaction with other cell cycle-associated proteins in mammary carcinoma. J Pathol 1999; 187: 200-206.
14. Spataro VJ, Litman H, Viale G et al. Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from International Breast Cancer Study Group Trial V. Cancer 2003; 97: 1591-1600.
15. Donnellan R, Kleinschmidt I, Chetty R. Cyclin E immunoexpression in breast ductal carcinoma: Pathologic correlations and prognostic implications. Hum Pathol 2001; 32: 89-94.
16. Schraml P, Bucher C, Bissing H et al. Cyclin E overexpression and amplification in human tumors. J Pathol 2003; 200: 375-382.
17. Nielsen NH, Arnelov C, Emdin SO et al. Cyclin E overexpression, a negative prognostic factor in breast cancer with strong correlation to oestrogen receptor status. Br J Cancer 1996; 74: 874-880.
18. Keyomarsi K, Tucker SL, Buchholz TA et al. Cyclin E and survival in patients with breast cancer. N Engl J Med 2003; 347: 1566-1575.
19. Ishihara A, Yoshida T, Tamaki et al. Tenascin expression in cancer cells and stroma in human breast cancer and its prognostic significance. Clin Cancer Res 1995; 1: 1035-1041.
20. Jahkola T, Toivonen T, Nordling S et al. Expression of tenascin-C in intraductal carcinoma of human breast: Relationship to invasion. Eur J Cancer 1998; 34: 1687-1692.
21. Adams M, Jones JL, Walker RA et al. Changes in Tenascin-C isoforms expression in invasive and preinvasive breast disease. Cancer Res 2002; 62: 3289-3297.
22. Kalembey I, Inada H, Nishima R et al. Tenascin-C upregulates metalloproteinase-9 in breast cancer cells: Direct and synergistic effects with transforming growth factor beta 1. Int J Cancer 2003; 105: 53-60.
23. Charpin C, Bonnier P, Garcia S et al. E-cadherin and beta-catenin expression in breast medullary carcinoma. Int J Oncol 1999; 15: 285-292.
24. Jacquemier J, Eisinger F, Nogues C et al. Histological type and syncythial growth pattern affect E-cadherin expression in a multifactorial analysis of a combined panel of sporadic and BRCA1 breast cancer. Int J Cancer 1999; 83: 45-49.
25. Bacus SS, Zelnick CR, Chin DM et al. Medullary carcinoma is associated with expression of intercellular adhesion molecule-1. Implication to its morphology and its clinical behavior. Am J Pathol 1994; 145: 1337-1348.
26. Gaffey MJ, Frierson HF Jr, Mills SE et al. Medullary carcinoma of the breast. Identification of lymphocytes subpopulations and their significance. Mod Pathol 1993; 6: 721-728.
27. Yakirevich E, Maroun L, Cohen O et al. Apoptosis, proliferation, and Fas (APO-I, CD95)/Fas ligand expression in medullary carcinoma of the breast. J Pathol 2000; 192: 166-173.
28. Tamiolakis D, Simopoulos C, Cheva A et al. Immunophenotypic profile of tumor infiltrating lymphocytes in medullary carcinoma of the breast. Eur J Gynecol Oncol 2002; 23: 433-436.
29. Liu S, Edgerton SM, Moore DH et al. Measures of cell turnover (proliferation and apoptosis) and their association with survival in breast cancer. Clin Cancer Res 2001; 7: 1716-1723.
30. Zambetti M, Bonadonna G, Valagussa P et al. Adjuvant CMF for node-negative and estrogen receptor-negative breast cancer patients. J Natl Cancer Inst Monogr 1992; 11: 77-83.